依维莫司联合依西美坦治疗表皮生长因子受体2阴性而激素受体阳性的内分泌治疗后的晚期乳腺癌

1.1 Everolimus, in combination with exemestane, is not recommended within its marketing authorisation for treating postmenopausal women with advanced human epidermal growth factor receptor 2 (HER2) negative hormone-receptorpositive breast cancer that has recurred or progressed following treatment with a non-steroidal aromatase inhibitor.

1.2 Women currently receiving everolimus for advanced breast cancer should be able to continue treatment until they and their clinician consider it appropriate to stop.

全文地址：